25 June 2020 - Having worked in the NHS as a hospital pharmacist before moving into market access roles in the pharma industry, Price has seen many changes that have affected the HTA process – and this has only accelerated in recent years.

“The scientific advances we are making today, many of which would have been improbable just a few years ago, are incredible. But they also present challenges to market access.

“Cell and gene therapies involve a one-time dose, which raises questions about how you measure treatment success when it may take some time to observe the long-term benefits, especially in terms of overall survival.”

Read Pharmaphorum article